Drug Reprograms Immune Responses to Target Glioblastoma

Investigators have discovered that using a novel drug agonist to target the STING pathway in preclinical models of glioblastoma reprogrammed previously suppressed immune responses, according to recent findings published in the Journal of Clinical Investigation.